ArticleESC heart failure2022
Prognostic value of the liver fibrosis marker fibrosis-5 index in patients with acute heart failure.
Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- The Liver as a Biomarker Organ in Heart Failure: Molecular Mechanisms, Hepatic Scores and Systemic Risk Stratification.International journal of molecular sciences · 2026Review
- Prognostic impacts of fibrosis-5 index in patients with chronic heart failure.Heart and vessels · 2026Article
- Reply to Comment on "Combination of the Fibrosis-4 Index and Carbohydrate Antigen 125 to Predict Morbidity and Mortality in Acute Heart Failure".Reviews in cardiovascular medicine · 2026Article
- Effect of median liver stiffness on chronic heart failure by alcohol intake in the NHANES population: A cross-sectional study.Medicine · 2026Article
- Association between noninvasive hepatic fibrosis indices and heart failure mortality.Medicine · 2026Observational
- The prognostic significance of the fibrosis-5 index in patients with acute decompensated heart failure.Journal of geriatric cardiology : JGC · 2025Article
- AI-powered model for predicting mortality risk in VA-ECMO patients: a multicenter cohort study.Scientific reports · 2025Article
- Diagnosis of Multiple Organ Dysfunction in Neonates with Hypoxic-Ischemic Encephalopathy: Vasoactive Inotropic Score, Renal Score, Fibrosis-5 Index and Lactate/Albumin Ratio.Diagnostics (Basel, Switzerland) · 2024Article
- Correlation of the FIB-4 Liver Biomarker Score with the Severity of Heart Failure.Medicina (Kaunas, Lithuania) · 2024Article
- Current Review of Heart Failure-Related Risk and Prognostic Factors.Biomedicines · 2024Review
- A Novel Liver Fibrosis Marker FIB-5 Index Predicted Response to Cardiac Resynchronization Therapy and Prognostic Outcomes in Patients With Heart Failure.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2024Article
- The role of urine chloride in acute heart failure.Scientific reports · 2024Article
- Prognostic Value of Fibrosis 4 (FIB-4) Index in Sepsis Patients.Journal of personalized medicine · 2024Article
- The Liver in Heart Failure: From Biomarkers to Clinical Risk.International journal of molecular sciences · 2023Review
- Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes: a narrative review.Biochemia medica · 2023Review
- Prognostic value of fibrosis-5 index combined with C-reactive protein in patients with acute decompensated heart failure.BMC cardiovascular disorders · 2023Article
- Prognostic value of the liver fibrosis marker fibrosis-5 index in patients with severe isolated tricuspid regurgitation: comparison with fibrosis-4 index.Heart and vessels · 2023Article
- Clinical and prognostic implications of hyaluronic acid in hospitalized patients with heart failure.Heart and vessels · 2023Article
- Relationship between haemodynamic indicators and haemogram in patients with heart failure.ESC heart failure · 2023Article
- Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsRecently, liver fibrosis markers, such as the fibrosis-4 index (FIB-4), have been shown to be associated with prognosis in patients with heart failure. The fibrosis-5 (FIB-5) index, which assesses albumin, alkaline phosphatase, aspartate transaminase, alanine aminotransferase and platelet count, is a simple liver fibrosis marker that was reported to be superior to FIB-4 for differentiation of liver fibrosis. This study aimed to compare the prognostic value of FIB-4 and FIB-5 in patients with heart failure. METHODS AND
resultsThe FIB-4 and FIB-5 scores were calculated at discharge in 906 patients hospitalized with heart failure. The patients were stratified into three groups based on their FIB-5 scores: low (n = 303), middle (n = 301), and high (n = 302) FIB-5 groups. The primary endpoint was a composite of cardiac death or rehospitalization for heart failure. The low FIB-5 group was older and had larger inferior vena cava diameters and higher brain natriuretic peptide levels than the other two groups. The primary endpoint occurred in 156 (51.5%), 110 (36.5%), and 54 patients (17.9%) in the low, middle, and high FIB-5 groups, respectively (P < 0.001). On Cox proportional hazard analysis, the low FIB-5 was independently associated with the primary endpoint after adjustment for confounding factors. The association was consistent in both patients with preserved and reduced left ventricular ejection fraction (LVEF), and there was no significant interaction between LVEF phenotypes in terms of the prognostic impact of FIB-5 (P for interaction = 0.311). FIB-5 was superior to FIB-4 as a prognostic indicator of the primary endpoint (continuous net reclassification improvement, 0.530; 95% confidence interval [CI], 0.399-0.662; P < 0.001; integrated discrimination improvement, 0.072; 95% CI, 0.057-0.088; P < 0.001).
conclusionsThe FIB-5 is a useful risk stratification marker with better prognostic value than FIB-4 in patients hospitalized with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.